Trial · NCT01975818
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
NCT01975818, Phase 2, Completed, Bayer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934. Trials, record NCT01975818. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01975818
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
- NCT number
- NCT01975818
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 201 participants, actual
- Lead sponsor
- Bayer
- Conditions
- Anemia, Renal Insufficiency, Chronic
- Interventions
- Molidustat (BAY 85-3934), Epoetin alfa/beta
- First posted
- 2013-11-05
- Last updated
- 2019-09-20
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in local laboratory hemoglobin level from baseline to the average during the last 4 weeks treatment period | Baseline and weeks 14 to 17 | |
| Secondary | Mean of the hemoglobin (Hb) levels in the target range (10.0 to 11.0 g/dL) | From week 14 to 17 | |
| Secondary | Mean of the hemoglobin levels in the target range (9.5 to 11.5 g/dL) | From week 14 to 17 | |
| Secondary | Change from baseline in Hb during active treatment | Baseline and weeks 14 to 17 | |
| Secondary | Number of patients with hemoglobin levels outside the target range | From week 14 to 17 | |
| Secondary | Dose level in the evaluation period | Up to 16 weeks | |
| Secondary | Duration of exposure on each dose level | Up to 16 weeks | |
| Secondary | Number of subjects requiring titration of dose | Up to 16 weeks | |
| Secondary | Number of participants with serious adverse events as a measure of safety and tolerability | Up to 16 weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 36005278 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01975818
GET https://conductscience.org/api/trials/v1/NCT01975818/registered